Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer. The first patients with locally advanced or metastatic nonsquamous non ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

MoA International Fund earns a High Process Pillar rating. The largest contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...

Company law mandates that either a private or public company create a Memorandum of Association (MOA) upon incorporation. When the company is first founded, the petition needs to be filed to the ...

Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...

diagnosis and early management NICE guideline 13 August 2025 Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] Technology appraisal guidance 20 August 2025 ...